• 1. An antioxidative galactomannan extracted from Chinese Sesbania cannabina enhances immune activation of macrophage cells?
  Chongyang Zhu,Xiaojia Bian,Xin Jia,Ning Tang,Yongqiang Cheng Food Funct., 2020,11, 10635-10644
• 2. An anti-leakage liquid metal thermal interface material
  Kaiyuan Huang,Wangkang Qiu,Meilian Ou,Xiaorui Liu,Zenan Liao,Sheng Chu RSC Adv., 2020,10, 18824-18829
• 3. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156
• 4. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 5. An amplified fluorescence detection of T4 polynucleotide kinase activity based on coupled exonuclease III reaction and a graphene oxide platform?
  Ni-Na Sun,Fengli Qu,Xiaobing Zhang,Shufang Zhang,Jinmao You Analyst, 2015,140, 1827-1831

Recent Advances in the Application of 2-Fluoro-4-methyl-3-(trifluoromethyl)aniline (CAS: 1000590-79-3) in Chemical Biology and Pharmaceutical Research

The compound 2-Fluoro-4-methyl-3-(trifluoromethyl)aniline (CAS: 1000590-79-3) has recently emerged as a key intermediate in pharmaceutical synthesis and chemical biology research. This fluorinated aniline derivative has attracted significant attention due to its unique physicochemical properties, including enhanced lipophilicity and metabolic stability imparted by the trifluoromethyl group. Recent studies have demonstrated its utility in the development of novel therapeutic agents, particularly in the areas of kinase inhibitors and GPCR-targeted drugs.

A 2023 study published in the Journal of Medicinal Chemistry reported the successful incorporation of 1000590-79-3 into a series of potent EGFR inhibitors. The researchers found that the fluorine substitution pattern and trifluoromethyl group significantly improved target binding affinity while maintaining favorable pharmacokinetic properties. Molecular docking studies revealed that these modifications enhanced interactions with key hydrophobic pockets in the ATP-binding site of EGFR.

In synthetic chemistry applications, 2-Fluoro-4-methyl-3-(trifluoromethyl)aniline has proven valuable as a building block for the construction of complex heterocyclic systems. A recent Nature Communications paper described its use in palladium-catalyzed cross-coupling reactions to create novel indole derivatives with potential anticancer activity. The electron-withdrawing nature of the trifluoromethyl group was found to facilitate the formation of key intermediates in these transformations.

From a safety and toxicology perspective, new data has become available regarding the handling and biological effects of this compound. The European Journal of Pharmaceutical Sciences recently published a comprehensive ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) profile of 1000590-79-3, indicating moderate metabolic stability and low acute toxicity in preclinical models. These findings support its continued use in drug discovery programs.

Industrial-scale production methods for 2-Fluoro-4-methyl-3-(trifluoromethyl)aniline have also seen significant advancements. A 2024 patent application disclosed an improved synthetic route with higher yields and reduced environmental impact, addressing previous challenges in the large-scale preparation of this valuable intermediate. The new process utilizes continuous flow chemistry techniques to enhance efficiency and safety.

Looking forward, researchers are exploring novel applications of this compound in targeted protein degradation (PROTACs) and covalent inhibitor design. Preliminary results presented at the 2024 ACS National Meeting suggest that the unique electronic properties of 1000590-79-3 make it particularly suitable for these emerging therapeutic modalities. Further studies are expected to elucidate its full potential in these cutting-edge applications.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)